I
Imagene AI
Biotech & Life Sciences · Tel Aviv-Yafo, Israel · Founded 2020
AI-based molecular testing for cancer MoreLess
Imagene AI operates within the digital pathology and precision medicine sectors, offering an AI-powered platform that delivers real-time molecular intelligence from digitized biopsy images. The company's core technology is a foundation model trained on over 1.5 million pathology slides, which facilitates the rapid profiling of a wide range of biomarkers for cancer.
This capability aims to significantly reduce the time required for patient diagnosis and treatment matching, which traditionally takes several weeks. By providing immediate molecular insights, the platform supports healthcare providers in making timely and informed decisions for precision oncology. The business model is structured as a Software as a Service (SaaS), providing adaptive capabilities for biomarker discovery and patient identification to its clients, which primarily include pharmaceutical companies and healthcare providers.
Recent funding rounds, including a significant Series B investment, underscore investor confidence in the company's approach to transforming cancer diagnostics and treatment. The platform's ability to function as a tool for precision medicine places it at the intersection of AI development and clinical application in oncology.
Keywords: digital pathology, precision medicine, AI diagnostics, biomarker discovery, oncology, molecular intelligence, SaaS, biopsy analysis, cancer treatment, healthcare technology
Company overview
Imagene AI company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2020
- Headquarters
- Tel Aviv-Yafo, Israel
- Employees
- 38
- Open positions
- 4
- Dealroom signal
- 85.3
Valuation & funding
Imagene AI funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jul 2025 | $23M | $92M | Larry Ellison | ↗ |
| SERIES A✓Equity / VC | May 2022 | $19M | $74M | Eyal Gura · David B. Agus · Larry Ellison | ↗ |
| SEED✓Equity / VC | May 2022 | $3M | $12M | Blumberg Capital | ↗ |
| SEED✓Equity / VC | Oct 2021 | $4M | $16M | Undisclosed | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 38 |
| 2025 | 35 |
| 2024 | 32 |
| 2023 | 29 |
| 2022 | 29 |
| 2021 | 14 |
Growth signals
Imagene AI website traffic
Latest recorded traffic for Imagene AI is 6.3K monthly website visits, up 80% over the last three months. Imagene AI's team grew 8.6% over the past year.
Hiring
Open positions at Imagene AI
Current openings linked to this company in Dealroom.
Comparisons
Imagene AI compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Imagene AI's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Imagene AI has talent and traffic
team presence
In the news
Latest news about Imagene AI
Recent press, funding announcements, and product moves mentioning Imagene AI — open to read from the original sources.
Market sentiment
What the market is saying about Imagene AI
An AI-synthesized read of the highest-engagement posts about Imagene AI on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Imagene AI’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.